Evaluation of commercially available immuno-magnetic agglutination in comparison to enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19

J Med Virol. 2021 May;93(5):3084-3091. doi: 10.1002/jmv.26854. Epub 2021 Feb 17.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Fast, accurate, and simple blood-based assays for quantification of anti-SARS-CoV-2 antibodies are urgently needed to identify infected individuals and keep track of the spread of disease.

Methods: The study included 33 plasma samples from 20 individuals with confirmed COVID-19 by real-time reverse-transcriptase polymerase chain reaction and 40 non-COVID-19 plasma samples. Anti-SARS-CoV-2 immunoglobulin M (IgM)/immunoglobulin A (IgA) or immunoglobulin G (IgG) antibodies were detected by a microfluidic quantitative immunomagnetic assay (IMA) (ViroTrack Sero COVID IgM + IgA/IgG Ab, Blusense Diagnostics) and compared to an enzyme-linked immunosorbent assay (ELISA) (EuroImmun Medizinische Labordiagnostika).

Results: Of the 33 plasma samples from the COVID-19 patients, 28 were positive for IgA/IgM or IgG by IMA and 29 samples were positive by ELISA. Sensitivity for only one sample per patient was 68% for IgA + IgM and 75% IgG by IMA and 80% by ELISA. For samples collected 14 days after symptom onset, the sensitivity of both IMA and ELISA was around 91%. The specificity of the IMA reached 100% compared to 95% for ELISA IgA and 97.5% for ELISA IgG.

Conclusion: IMA for COVID-19 is a rapid simple-to-use point-of-care test with sensitivity and specificity similar to a commercial ELISA.

Keywords: SARS-CoV-2; blood; immuno-magnetic agglutination assay; rapid IgG-IgM-IgA combined test; surveillance.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • COVID-19 / diagnosis*
  • COVID-19 Testing / methods*
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Female
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin A / isolation & purification
  • Immunoglobulin G / blood
  • Immunoglobulin G / isolation & purification
  • Immunoglobulin M / blood
  • Immunoglobulin M / isolation & purification
  • Immunomagnetic Separation / methods*
  • Male
  • Middle Aged
  • Point-of-Care Testing*
  • RNA, Viral
  • Reverse Transcriptase Polymerase Chain Reaction
  • SARS-CoV-2*
  • Sensitivity and Specificity

Substances

  • Immunoglobulin A
  • Immunoglobulin G
  • Immunoglobulin M
  • RNA, Viral

Grants and funding